FDA Warns Boothwyn Pharmacy Over Sterility, Potency Issues

Sterile compounders operating under Section 503A of the FDCA should read Boothwyn Pharmacy, LLC's January 2026 warning letter as a precise map of where FDA investigators will focus scrutiny. The letter, issued by CDER on January 16, 2026, follows a May–June 2025 inspection of the firm's Kennett Square, Pennsylvania facility and cites adulteration findings across three distinct failure categories: environmental controls, subpotency, and sterility.

Investigators documented that Boothwyn failed to conduct adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area, a foundational sterility assurance requirement. Production surfaces were also characterised as porous, difficult to clean, or visibly contaminated, conditions that directly compromise aseptic processing integrity regardless of downstream testing outcomes.

The potency findings carry equal regulatory weight. Boothwyn's Fluorescein 2% Ophthalmic Solution tested at 85.9% and 76.1% of labeled strength across two lots, falling below compendial standards and triggering adulteration status under section 501(b) of the FDCA. Semaglutide 2.5 mg/mL Injection returned a potency of 79.9% on a distributed lot. A Tirzepatide 17 mg/mL combination injection failed sterility testing outright after release and distribution, the most serious of the cited violations.

The firm's corrective timeline is already on record. Boothwyn initiated a voluntary recall on July 9, 2025, covering all in-expiry lots with out-of-specification results and all lots filled from the same bulk stock solution. Production of all GLP-1 sterile injectables ceased, and on August 20, 2025, the firm notified FDA of intent to resume. FDA's warning letter post-dates that notification, signalling that the agency did not consider the submitted responses, dated July 1 and July 31, 2025, sufficient to close the matter.

For QA directors at 503A and 503B compounders, the Boothwyn record reinforces that release testing alone does not satisfy sterility assurance obligations; environmental qualification, airflow validation, and surface integrity must be demonstrable before product reaches patients. The concurrent potency failures across multiple product lines also suggest systemic gaps in formulation verification and in-process controls rather than isolated batch deviations.

FDA's acceptance of a resumption notification without closing the warning letter sets a clear checkpoint: Boothwyn's path forward will require documented remediation of each cited observation before the agency is likely to treat the facility as compliant.

Source: FDA Center for Drug Evaluation and Research (CDER) via FDA.gov Warning Letters database, January 16, 2026. Inspection conducted May 12–June 9, 2025.